SCHEMBL6862677

SCHEMBL6862677

CC(C)(C(=O)Cl)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.CC(C)(C(=O)Nc1ccccc1-c1ccccc1N)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 4/20 0.65
P2RX1 P51575 1/20 0.43
PTGS1 P23219 3/20 0.41
GPBAR1 Q8TDU6 1/20 0.41
TP53 P04637 1/20 0.40
TACR3 P29371 2/20 0.39
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HDAC3 O15379 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
ABCG2 Q9UNQ0 1/20 0.37
PDK1 Q15118 3/20 0.36
PDK2 Q15119 3/20 0.36
PDK3 Q15120 3/20 0.36
PDK4 Q16654 3/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6866661 0.94 TACR1 (0.73) TACR1P2RX1PTGS1GPBAR1TP53
SCHEMBL6869375 0.78 TACR1 (0.70) TACR1GPBAR1TP53TACR3ALDH1A1
SCHEMBL1202442 0.72 CES2 (0.50) TACR1P2RX1TACR3ALDH1A1HDAC3
SCHEMBL5966342 0.70 TACR1 (0.62) TACR1GPBAR1
SCHEMBL5741683 0.69 TACR1 (0.64) TACR1TACR3CYP1A2CYP2C9ALDH1A1
SCHEMBL5741984 0.69 TACR1 (0.64) TACR1TACR3CYP1A2CYP2C9ALDH1A1
SCHEMBL6862560 0.69 TACR1 (0.73) TACR1GPBAR1TACR3
SCHEMBL5740163 0.68 TACR1 (0.59) TACR1TP53CYP1A2CYP2C9ALDH1A1
SCHEMBL24574910 0.68 ALDH1A1 (0.66) TACR1P2RX1PTGS1TP53ALDH1A1
SCHEMBL6866855 0.68 TACR1 (0.55) TACR1P2RX1GPBAR1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1171419-B1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR HOFFMANN LA ROCHE (CH) 2004-12-29 EP disclosed
US-6552088-B2 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor HOFFMANN-LA ROCHE INC. 2003-04-22 US disclosed
US-20020040060-A1 Biphenyl derivatives BOS MICHAEL (CA) 2002-04-04 US disclosed
EP-1171419-A1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2002-01-16 EP disclosed
US-6291465-B1 Biphenyl derivatives HOFFMANN-LA ROCHE INC. 2001-09-18 US disclosed
WO-2000053572-A1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2000-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040060-A1 Biphenyl derivatives NR1H4, NR1H2, NR1H3 TACR1 16/4885P2RX1 998/4885PTGS1 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.